Welcome to our dedicated page for Onassis Holdings news (Ticker: ONSS), a resource for investors and traders seeking the latest updates and insights on Onassis Holdings stock.
Onassis Holdings Corp. (ONSS) operates as an OTC-traded biotech-focused holding company centered on longevity and cellular rejuvenation technologies. Company updates describe work in epigenetic reprogramming, licensed rejuvenation technology, and the Ananda Labs Inc. subsidiary, which focuses on patented proteins intended to rejuvenate aged cells while preserving their distinct properties.
Recurring news also covers capital-raising initiatives under Regulation A+, Regulation D, and Regulation S, relationships with investment banks and broker-dealers, shareholder communications tools, and advisory-board appointments tied to international law, trade, and cross-border corporate affairs.
Onassis Holding Corp (OTC: ONSS) announced the appointment of Esq. Paz Itzhaki-Weinberger to its Advisory Board on November 5, 2025.
He will lead the company's strategy on international law, trade, and cross-border corporate affairs. Itzhaki-Weinberger combines engineering and legal backgrounds, has held senior roles at Microsoft, managed multiple hi-tech ventures, founded PIWLAW (named among the Top 200 Law Firms Worldwide 2014–2025), and currently serves as CEO and Chairman of IWC Limited.
He previously led PatentsFund.com, advises technology firms on IPO and M&A transactions, holds degrees in Computer Science and Law, and is fluent in English, Hebrew, Japanese, German, and Arabic. He is a member of multiple legal and technical organizations including the Israel Bar Association and IEEE.
Onassis Holding Corp (OTC: ONSS) has announced its plans to launch a Regulation A+ offering to raise up to $75 million from the public. The biotech-focused holding company has partnered with Dalmore Group, a leading investment bank with over $2 billion in raised capital and more than 1 million processed transactions.
Dalmore Group, which has onboarded over 270 Reg A+ issuers since 2021, brings 16 years of experience and will provide strategic partnerships, marketing support, and secondary trading solutions for the offering.
Onassis Holding Corp (OTC: ONSS), a wellness and biotech focused holding company, has announced the launch of a Regulation A+ financing round, aiming to raise up to $75 million annually from the public. The company has retained Dalmore Group, an investment bank with over $3.6 billion in live Reg A+ offerings, to facilitate this process.
Dalmore Group, with its 16 years of experience, has on-boarded over 270 Reg A+ issuers since 2021, positioning itself as a leader in Reg A+ financing services. This partnership is expected to provide Onassis with access to Dalmore's extensive network, including marketing and PR experts, syndication partnerships, and secondary trading solutions for Reg A+ issuers.
Summary not available.
Summary not available.
Summary not available.
Onassis Holdings Corp (OTC: ONSS) has partnered with SRAX (NASDAQ: SRAX) to enhance investor communication and streamline activities with potential investors and existing shareholders. SRAX's Sequire platform will provide Onassis with real-time market data, improving the overall investor experience. Eliron Yaron, Chairman of Onassis, emphasized that effective communication is crucial for the company's plans for growth in the coming year. Onassis focuses on the distribution of nutraceuticals and herbal-based medications, collaborating with top nutrition experts to innovate and ensure effective ingredients.
Onassis Holding Corp (OTC: ONSS) announced the initiation of a Regulation A+ financing round to raise up to $75 million, aimed at expanding its operations in wellness and healthcare. The company has partnered with Dalmore Group, recognized for its success in facilitating Reg A+ offerings, having onboarded over 175 issuers since 2019. Onassis is focused on distributing nutraceuticals and herbal medications, with plans for new product manufacturing. Their products include immune-boosting supplements and they are currently working on an Investigational Medicinal Product for Covid-19.
Onassis Holding Corp (OTC: ONSS) has launched sales of its Extrax CBD vape formulations developed in the UK, now available in the EU and North America. These products offer five unique mood experiences and feature broad-spectrum CBD with no stabilizers or additives, promoting high absorption. Extensive lab tests yielded positive results, leading to the opening of a dedicated CBD vape store. Each vape contains 320mg CBD and 80% total cannabinoids, with flavors like Lemon Cake and Pina Colada. Onassis aims to enhance wellness through innovative, natural extracts.